You qualify if you indirectly purchased, paid for, or reimbursed covered generic prescription drugs for personal use between May 1, 2009 and Dec. 31, 2019. Individual consumers can claim the $475 million Sandoz and Sun/Taro funds, while health plans and other third-party payers can claim additional funds.
End-payer means you did not buy directly from the maker. You paid at a pharmacy, paid a copay, or reimbursed the cost for yourself or a family member. Fine Kaplan and Black states the class covers consumers and third-party payers for personal use, not resale, in the class notice for generic drug end-payers.
Table of Contents
- What is the $533 million case?
- Do you qualify as a consumer?
- What can third-party payers claim?
- How do you file by Nov. 9, 2026?
- Do not file in the wrong settlement
What is the $533 million case?
The case is In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724 in the Eastern District of Pennsylvania.
MCAG identifies it as alleging makers fixed prices and divided markets for generic drugs. The federal end-payer total has three parts. MCAG reports $275 million from Sandoz/Fougera, $200 million from Sun/Taro, and about $58 million from Heritage/Apotex combined in the MCAG settlement breakdown.
Do you qualify as a consumer?
You must have paid for a listed drug for personal use, not for resale. The purchase window is fixed. It starts May 1, 2009 and ends Dec. 31, 2019.
Geography also matters. Money reports coverage in 48 states excluding Indiana and Ohio, plus D.C., Puerto Rico and the U.S. Virgin Islands. Purchases reimbursed by Medicaid do not count.
- You bought or paid a copay for a listed generic drug
- You bought in a covered state or territory during the window
- You used the drug for personal or family use
- No Medicaid payment covered that purchase
What can third-party payers claim?
Third-party payers include health plans, insurers, and self-funded employers that reimbursed drug costs. They have broader access than individual shoppers. They can pursue all three federal end-payer groups.
Individual consumers have a narrower path. The Settlement Administrator limits the official consumer claim form to the Sandoz and Sun/Taro classes. That leaves the Heritage/Apotex funds to third-party payers.
How do you file by Nov. 9, 2026?
File online at GenericDrugsEndPayerSettlement.com or by mail postmarked by Nov. 9, 2026. Include at least one proof of purchase for each named drug you claim.
The Settlement Administrator instructions describe that proof and deadline in the November settlement deadlines roundup. Use pharmacy receipts, printouts, or insurer records that show drug, date, and payment. List each drug separately. Keep copies of everything you send.
Do not file in the wrong settlement
A separate state-led deal covers different makers and a different site. The Utah Department of Commerce identifies it as a $96.5 million settlement with Glenmark, Lannett, Bausch, Apotex, Heritage and Emcure in the Utah consumer compensation notice. That state deal uses AGGenericDrugs.com with a March 8, 2027 deadline.
Do not use that site for the federal $533 million claim. Use only the federal end-payer site and meet the Nov. 9, 2026 postmark.